Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Efficacy of Rifabutin in the Treatment of Serious and Life Threatening Infections Due to Mycobacterium Avium Complex, or Drug Resistant Mycobacterium Tuberculosis, or Other Drug Resistant Mycobacterium

NCT03164291 is registered in ClinicalTrials.gov with The University of Texas Health Science Center at Tyler as lead sponsor.

NCT NCT03164291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03164291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Efficacy of Rifabutin in the Treatment of Serious and Life Threatening Infections Due to Mycobacterium Avium Complex, or Drug Resistant Mycobacterium Tuberculosis, or Other Drug Resistant Mycobacterium
Lead sponsor
The University of Texas Health Science Center at Tyler
Phase
Phase 3
Overall status
Completed
Start date
June 30, 1984
Completion date
May 18, 2017
Enrollment
170 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nontuberculous mycobacterial infections